Ongoing clinical research into the pharmacokinetic and pharmacodynamic effects of the immunosuppressant mycopheonlic acid faces challenges due to the overlap of its metabolites, mycophenolic acid Glucoronide (MPAG) and mycophenolic acid acyl-glucoronide (AcMPAG), with the parent drug.
With the use of the ACQUITY UPLC I-Class PLUS separation coupled with the Xevo TQD for mass detection, this challenge can be faced with ease. The chromatographic resolution of the ACQUITY UPLC I-Class PLUS of the metabolites mycophenolic acid glucoronide (MPAG) and mycophenolic acid acyl-glucoronide (AcMPAG) reduces interferences, providing greater specificity for clinical research.
Mycophenolic acid is an immunosuppressant agent that acts by inhibiting inosine monophosphate dehydrogenase in the purine synthesis pathway required for the growth of B and T cells. Mycophenolic acid is metabolized into mycophenolic acid glucuronide (MPAG) and mycophenolic acid acyl-glucuronide (AcMPAG).
Existing methods for the analysis of mycophenolic acid lack the ability to separate mycophenolic acid from its metabolites. The ACQUITY UPLC I-Class PLUS and Xevo TQD mass spectrometer are able to overcome these challenges and chromatographically separate mycophenolic acid from its metabolites in a shorter time.